ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Apr 7, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how a chatbot and activity monitoring can help manage symptoms for patients undergoing treatment for lung, gastrointestinal, or head and neck cancers. The goal is to see if this technology can help identify health issues early, so patients can get the right care before they need to visit the hospital. Researchers hope that by using this system, they can reduce unnecessary trips to the emergency room and hospital stays.

To participate in this trial, you need to be an adult over 18 years old with a diagnosis of one of the cancers mentioned and currently receiving both chemotherapy and radiation. You should also have a mobile device that can send and receive text messages and can connect to a FitBit to track your activity. If you are able to read and respond to messages in English and can give your consent to be part of the study, you may be eligible. Participants can expect to use the chatbot to communicate about their symptoms and activity levels, helping to ensure they receive timely support during their treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (age \>18 years) with a diagnosis of a head and neck, lung, gastrointestinal cancer, that are receiving concurrent chemotherapy and radiation treatment.
• • Possession of a mobile device that can receive SMS texts and can deliver FitBit data wirelessly
• • Ability read and respond in English
• • Ability to provide informed consent to participate in the study
• Exclusion Criteria:
• • Patients who are bed bound at baseline (ECOG 4)
• • Patients who rely on a wheelchair for ambulation